SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc.

Solesence ( ($SLSN) ) has released a notification of late filing. Solésence, Inc. has filed a Form 12b-25 notifying investors of a delay in submitt...

Solésence delays quarterly report amid accounting review

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK), SELLAS Life Sciences Group (SLS...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Solstice Minerals Limited ( ($AU:SLS) ) has provided an announcement. Solstice Minerals has released an investor presentation outlining general inf...

Solstice Minerals updates investors on copper-gold exploration profile and disclosures

In a report released today, Paul Howard CFA from Canaccord Genuity maintained a Buy rating on Solstice Minerals Limited, with a price target of A$2...

Canaccord Genuity Keeps Their Buy Rating on Solstice Minerals Limited (SLS)

Solstice Minerals Limited ( ($AU:SLS) ) has issued an update. Solstice Minerals Limited has reported the lapse of 212,959 performance rights that w...

Solstice Minerals Reports Lapse of Performance Rights

SELLAS Life Sciences Group ( ($SLS) ) has issued an update. On July 24, 2026, a sole arbitrator at the Hong Kong International Arbitration Centre d...

SELLAS Life Sciences Faces Adverse Arbitration Ruling

Solstice Minerals Limited ( ($AU:SLS) ) just unveiled an update. Solstice Minerals Limited has issued 180,366 unquoted performance rights under its...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$12.78	0.00%	5.67M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$12.78	0%	5.67M
3
4
5
6

SLS

Get SELLAS Life Sciences Group, Inc. Data in Excel

Get SELLAS Life Sciences Group, Inc. Data in Excel